Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021

Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children

Matt WassermanComments to Author , Ruth Chapman, Rotem Lapidot, Kelly Sutton, Desmond Dillon-Murphy, Shreeya Patel, Erica Chilson, Vincenza Snow, Raymond Farkouh, and Stephen Pelton
Author affiliations: Pfizer Inc., New York, New York, USA (M. Wasserman, E. Chilson, V. Snow, R. Farkouh); Evidera Market Access Ltd, London, UK (R. Chapman, K. Sutton, D. Dillon-Murphy, S. Patel); Boston University School of Medicine, Boston, Massachusetts, USA (R. Lapidot, S. Pelton)

Main Article

Table 3

Estimated average incidence of otitis media cases and visits averted by PCVs, United States, 1997–2019*

Measure 1997–1999 2000–2009 2010–2019 Cumulative
Average incidence of visits per 100 children 78 59 46 NA
Expected visits† NA 154,269,900 155,511,917 309,781,817
Estimated visits NA 119,429,938 93,025,190 212,455,128
Visits averted‡ NA 34,839,962 62,486,726 97,326,688

*Values are rounded to the nearest whole numbers. PCV7 was approved for use in the United States in 2000; PCV13 was approved for use in the United States in 2010. NA, not applicable; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV.
†Visits expected if PCVs had not been introduced.
‡Calculated by subtracting estimated visits from expected visits.

Main Article

Page created: April 15, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.